抗肿瘤分子靶向药物相关皮炎研究进展

王致红, 张铭予, 李春雨, 李国辉

中国药学杂志 ›› 2021, Vol. 56 ›› Issue (19) : 1551-1556.

PDF(1054 KB)
中国药学杂志
PDF(1054 KB)
中国药学杂志 ›› 2021, Vol. 56 ›› Issue (19) : 1551-1556. DOI: 10.11669/cpj.2021.19.003
综述

抗肿瘤分子靶向药物相关皮炎研究进展

  • 王致红, 张铭予, 李春雨*, 李国辉*
作者信息 +

Research Progress of Antineoplastic Molecular Targeted Drug-Related Dermatitis

  • WANG Zhi-hong, ZHANG Ming-yu, LI Chun-yu*, LI Guo-hui*
Author information +
文章历史 +

摘要

抗肿瘤分子靶向药物因其靶向性强、安全性高、毒副作用小等优点已广泛用于恶性肿瘤的治疗。然而,分子靶向药物相关皮炎不仅影响了患者的生活质量和用药依从性,也影响其临床疗效的发挥。目前关于皮炎的发病机制尚不清楚,也缺乏有效的治疗手段。笔者从皮炎概况、治疗现状、发病机制、动物模型的常见造模方法,以及观察指标等5个方面进行综述,以期为分子靶向药物合理用药及不良反应研究提供科学依据。

Abstract

Antineoplastic molecular targeting drugs have been widely used in the treatment of malignant tumors because of their strong targeting, high safety and low side effects. However, molecular targeted drug-associated dermatitis not only affects the quality of life and drug compliance of patients, but also affects its clinical efficacy. At present, the pathogenesis of dermatitis is not clear, and there is a lack of effective treatment. This article reviews the general situation, treatment status, pathogenesis, common modeling methods of animal models and observation indicators of dermatitis, in order to provide scientific basis for the rational use of molecular targeted drugs and adverse reactions.

关键词

肿瘤 / 分子靶向药物 / 表皮生长因子受体酪氨酸激酶抑制 / 皮炎 / 不良反应 / 合理用药

Key words

tumor / molecular targeted drug / EGFR-TKIs / dermatitis / adverse reaction / rational drug use

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
王致红, 张铭予, 李春雨, 李国辉. 抗肿瘤分子靶向药物相关皮炎研究进展[J]. 中国药学杂志, 2021, 56(19): 1551-1556 https://doi.org/10.11669/cpj.2021.19.003
WANG Zhi-hong, ZHANG Ming-yu, LI Chun-yu, LI Guo-hui. Research Progress of Antineoplastic Molecular Targeted Drug-Related Dermatitis[J]. Chinese Pharmaceutical Journal, 2021, 56(19): 1551-1556 https://doi.org/10.11669/cpj.2021.19.003
中图分类号： R969   

参考文献

[1] CAO M M, CHEN W Q. Epidemiology of cancer in China and the current status of prevention and control[J]. Chin J Clin Oncol(中国肿瘤临床), 2019, 46(3):145-149.
[2] HAN D, CHU W G,DAI F. Analysis of 125 cases of adverse reactions of bevacizumab injection[J]. Chin J Hosp Pharm(中国医院药学杂志), 2013, 33(9):749-751.
[3] KLUFA J, BAUER T, HANSON B, et al. Hair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapy[J]. Sci Transl Med, 2019, 11(522):DOI: 10.1126/scitranslmed.aax2693.
[4] Guiding principles for Clinical Application of New antineoplastic drugs (2019 Edition)[J]. J Multi Cancer Manage (Elect Ver)(肿瘤综合治疗电子杂志), 2020, 6(1):16-47.
[5] BAUDINO T A. Targeted Cancer Therapy:The Next Generation of Cancer Treatment[J]. Curr Drug Discov Technol, 2015, 12(1):3-20.
[6] WU Y L, ZHOU C, LIAM C K, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer:analyses from the phase III, randomized, open-label, ENSURE study[J]. Ann Oncol, 2015, 26(9):1883-1889.
[7] WU J X, HE Q, YE F, et al. EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations:a meta-analysis of randomized controlled trials[J]. Onco Targets Ther, 2018, 11:6803-6810.
[8] HU J, LIN L Z, LUO Y Q, et al. EGFR-TKI ADR Management Chinese Expert Consensus[J]. Chin J Lung Cancer(中国肺癌杂志), 2019, 22(2):57-81.
[9] MO K T S, WU Y L, THONGPRASERT S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361(10):947-957.
[10] Kainis I, Syrigos N, Kopitopoulou A, et al. Erlotinib-Associated Rash in Advanced Non-Small Cell Lung Cancer:Relation to Clinicopathological Characteristics, Treatment Response, and Survival[J]. Oncol Res, 2018, 26(1):59-69.
[11] YANG Z, HACKSHAW A, FENG Q, et al. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer:A meta-analysis[J]. Int J Cancer, 2017, 140(12):2805-2819.
[12] PETRELLI F, ARDITO R, GHIDINI A, et al. Different Toxicity of Cetuximab and Panitumumab in Metastatic Colorectal Cancer Treatment:A Systematic Review and Meta-Analysis[J]. Oncology, 2018, 94(4):191-199.
[13] ALGAZI A P, ESTEVE-PUIG R, NOSRATI A, et al. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma[J]. Pigment Cell Melanoma Res, 2018, 31(1):110-114.
[14] LIU S, KURZROCK R. Understanding Toxicities of Targeted Agents:Implications for Anti-tumor Activity and Management[J]. Semin Oncol, 2015, 42(6):863-875.
[15] JIANG S S,HU L Q. Clinical effect and Mechanism of modified Yangyin jiedu decoction in the treatment of Epidermal growth Factor receptor tyrosine Kinase inhibitor related rash in patients with Lung Cancer[J]. Chin J Postgrad Med(中国医师进修杂志), 2020, 43(7):619-624.
[16] LU J Y, CHEN L J,GUO Z Y. Observation on the effect of external application of compound honeysuckle decoction combined with chlortetracycline eye ointment on the degree and duration of symptoms in the treatment of skin rash caused by EGFRIs[J]. J Liaoning Univ Tradit Chin Med(辽宁中医药大学学报), 2020, 22(8):191-194.
[17] CHEN X R. Clinical observation of Xiaoleng decoction on EGFR-TKIs-related rash (Yin deficiency Type) of Lung Adenocarcinoma[D]. Urumqi:Xinjiang Medical University, 2020.
[18] CHEN X Z, TIAN H Q, ZHOU H Y, et al. Study on the efficacy of compound Xiaofeng Powder combined with compound Yellow Water in the treatment of skin toxicity of Epidermal growth Factor receptor Inhibitors:a report of 40 cases[J]. Global Tradit Chin Med(环球中医药), 2014, 7(S1):54-55.
[19] CUI H J, WANG H Y, BAI Y P, et al. Clinical observation on the treatment of 20 cases of Epidermal growth Factor receptor antagonist-related skin eruption with traditional Chinese Medicine prescription "Anti-itching and skin-relieving liquid"[J]. J China-Japan Friend Hosp(中日友好医院学报), 2012, 26(2):97-98.
[20] WANG X W,CHEN R H. Analysis of 23 cases of gefitinib-related rash treated by TCM syndrome differentiation[J]. Inner Mongolia Tradit Chin Med(内蒙古中医药), 2008, 27(24):9-10.
[21] Macdonald J B, Macdonald B, Golitz L E, et al. Cutaneous adverse effects of targeted therapies:Part I:Inhibitors of the cellular membrane[J]. J Am Acad Dermatol, 2015, 72(2):203-218; quiz 219-220.
[22] YE C B,ZHOU Y. Comparison of treatment guidelines for atopic dermatitis in different countries and regions[J]. Chin J Dermatovenereol(中国皮肤性病学杂志),2020, 34(11): 1331-1336,1340.
[23] MASCIA F, MARIANI V, GIROLOMONI G, et al. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation[J]. Am J Pathol, 2003, 163(1):303-312.
[24] LICHTENBERGER B M, GERBER P A, HOLCMANN M, et al. Study on the effect and mechanism of experimental prescription "Qiyin three two three" in the treatment of skin rash induced by gefitinibEpidermal EGFR controls cutaneous host defense and prevents inflammation[J]. Sci Transl Med, 2013, 5(199):199ra111. doi: 10.1126/scitranslmed.3005886.
[25] WARD N L, BHAGATHAVULA N, JOHNSTON A, et al. Erlotinib-induced skin inflammation is IL-1 mediated in KC-Tie2 mice and human skin organ culture[J]. J Invest Dermatol, 2015, 135(3):910-913.
[26] WAN L Q. Study on the effect and mechanism of experimental prescription "Qiyin three two three" in the treatment of skin rash induced by gefitinib[D]. Beijing:Beijing University of traditional Chinese Medicine, 2019.
[27] GURULE N J, HEASLEY L E. Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses[J]. Cancer Drug Resist, 2018, 1:118-125.
[28] MASCIA F, MARIANI V, GIROLOMONI G, et al. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation [J]. Am J Pathol, 2003,163(1):303-312.
[29] ZHANG Z H,HUA B J. Experience of Huabaojin in the treatment of rash caused by epidermal growth factor receptor tyrosine kinase inhibitor[J]. Chin J Tradit Chin Med(中华中医药杂志), 2020, 35(5):2497-2500.
[30] SONG Y Z. Establishment of an animal model of adverse reactions such as epidermal growth factor receptor inhibitor-related rash[D]. Beijing University of traditional Chinese Medicine, 2017.
[31] DIDOVIC S, OPITZ F V, HOLZMANN B, et al. Requirement of MyD88 signaling in keratinocytes for Langerhans cell migration and initiation of atopic dermatitis-like symptoms in mice[J]. Eur J Immunol, 2016, 46(4):981-992.
[32] YOO J, MANICONE A M, MCGUIRE J K, et al. Systemic sensitization with the protein allergen ovalbumin augments local sensitization in atopic dermatitis[J]. J Inflamm Res, 2014, 7:29-38.
[33] LI H, GAO Q, WANG Y T, et al. Research progress on the establishment of atopic dermatitis model in mice[J]. Armed Police Med(武警医学), 2015, 26(1):99-102.
[34] WANG J X. Observation on the Therapeutic effect of Coix seed extract on mice with BALB/c Atopic Dermatitis[D]. Tianjin:Tianjin Medical University, 2018.
[35] MENG Z Y, ZHAO Z G, DU H B, et al. Methodological progress in establishing animal models of atopic dermatitis[J]. J Med Res(医学研究杂志), 2010, 39(4):124-125.
[36] CHAN L S, ROBINSON N, XU L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease:an experimental animal model to study atopic dermatitis[J]. J Invest Dermatol, 2001, 117(4):977-983.
[37] SONG Y Z, XU Y B, DENG B, et al. Establishment of a mouse model of skin adverse reaction induced by erlotinib[J]. Chin J Comp Med(中国比较医学杂志), 2017, 27(1):16-21.
[38] SURGULADZE D, DEEVI D, CLAROS N, et al. Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice[J]. Cancer Res, 2009, 69(14):5643-5647.
[39] MASCIA F, LAM G, KEITH C, et al. Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy[J]. Sci Transl Med, 2013, 5(199):199ra110.
[40] CARBONE M L, LULLI D, PASSARELLI F, et al. Topical Plant Polyphenols Prevent Type I Interferon Signaling in the Skin and Suppress Contact Hypersensitivity[J]. Int J Mol Sci, 2018, 19(9):2652.

基金

中国癌症基金会北京希望马拉松专项基金资助( LC2020A28)
PDF(1054 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉